Reciprocal regulation of endothelin-1 and nitric oxide: Relevance in the physiology and pathology of the cardiovascular system

International Review of Cytology

Volumn 209, Issue , 2001, Pages 241-272

  Rossi, Gian Paolo ^a   Seccia, Teresa Maria ^a   Nussdorfer, Gastone G ^b  

^a University Hospital   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atherosclerosis; Blood pressure; Cardiovascular system; Endothelin 1; Hypertension; Nitric oxide

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPERTENSION; MEDIATOR RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SMOOTH MUSCLE FIBER; STIMULATION; SYNTHESIS; VASCULAR SMOOTH MUSCLE;

EID: 0034813319     PISSN: 00747696     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0074-7696(01)09014-3     Document Type: Review

References (196)

1. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice
2. Nitric oxide (EDRF) enhances the vasorelaxing effect of dihydropyridine calcium antagonists in isolated human middle cerebral arteries
3. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on cholesterol-enriched diet
4. Endothelial cytosolic proteins bind to the 3′ untranslated region of endothelial nitric oxide synthase mRNA: Regulation by tumor necrosis factor alpha
5. Enzymatic function of nitric oxide synthases
6. Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1β and INF-gamma
7. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction
8. Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats
9. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
10. Differential modulation of the renal and myocardial endothelin system by angiotensin II in vivo. Effects of chronic selective ETA receptor blockade
11. Growth regulatory properties of endothelins
12. Endothelin-1 inhibits cytokine-stimulated transcription of inducible nitric oxide synthase in glomerular mesangial cells
13. Cloning and sequencing of the proximal promoter of the rat iNOS gene: Activation of NF-κB is not sufficient for transcription of the iNOS gene in rat mesangial cells
14. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats
15. The calcium-antagonist nifedipine stimulates endothelial NO release in therapeutical concentrations
16. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro
17. 17β-estradiol modulates endothelin-1 expression and release in human endothelial cells
18. Peroxisome proliferator-activated receptors in the cardiovascular system
19. Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3′-untranslated region
20. L-Arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study
21. L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects
22. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits
23. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
24. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide
25. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice
26. Nitric oxide: A physiologic messenger molecule
27. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells
28. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease
29. Coronary endothelial dysfunction in the hypertensive patient: From myocardial ischemia to heart failure
30. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction
31. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite
32. Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension
33. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo
34. Endothelin and pulmonary hypertension
35. Reactive oxygen species modulate endothelin-1-induced c-fos gene expression in cardiomyocytes
36. Is atherosclerosis an arginine defiency disease?
37. Arginine: A new therapy for atherosclerosis?
38. Tetrahydrobiopterin and endothelial nitric oxide synthase activity
39. Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide
40. Actions of 1,4-dihydropyridines in isolated mesenteric vascular beds
41. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
42. Homocysteine and endothelial function
43. Endothelial dysfunction in human disease
44. Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia
45. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide
46. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells
47. Treatment of hypertension with ascorbic acid
48. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension
49. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
50. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell
51. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin
52. Endothelial cell-specific regulation of the murine endothelin-1 gene
53. Endothelin-1 and smooth muscle cells: Induction of jun amino-terminal kinase through an oxygen radical-sensitive mechanism
54. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor
55. NO: The primary EDRF
56. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)
57. Role of NF-kB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2
58. Temporal regulation of endothelial ET-1 and eNOS expression in intact human conduit vessels exposed to different intraluminal pressure levels at physiological shear stress
59. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat
60. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis
61. Endothelin-1 immunoreactivity and mRNA in the transplanted human heart
62. Endothelins in health and disease: An overview
63. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis
64. The endothelin system and its potential as a therapeutic target in cardiovascular disease
65. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries
66. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension
67. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo
68. Adrenomedullin, a multifunctional regulatory peptide
69. Regulation of adrenal vasculature tone: Role of endothelin-1 and nitric oxide
70. The relationship between adrenal vascular events and steroid secretion: The role of mastcells and endothelin
71. Endothelin-1 inhibits induction of nitric oxide synthase and GTP cyclohydrolase-1 in rat mesangial cells
72. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension
73. The paracrine endothelin system: Pathophysiology and implications in clinical medicine
74. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells
75. Nitric oxide: A unique endogenous signaling molecule in vascular biology
76. Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells
77. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells
78. Induction of endothelin-1 gene by angiotension and vasopression in endothelial cells
79. Mechanism of endothelin-1(1-31)-induced calcium signaling in human coronary artery smooth muscle cells
80. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation, but not the inhibition of migration, is mediated through the activation of inducible nitric oxide synthase
81. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells
82. Molecular cloning of endothelial, inducible nitric oxide synthase gene from rat aortic endothelial cell
83. Nitric oxide and the proliferation of vascular smooth muscle cells
84. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters
85. Balloon injury and interleukin-1 beta induce nitric oxide synthase activity in rat carotid arteries
86. The role of endothelin-converting enzyme-1 in the development of α1-adrenergic-stimulated hypertrophy in cultured neonatal rat cardiac myocytes
87. Regulation of inducible nitric oxide synthase gene by interleukin-1β in rat vascular endothelial cells
88. Endothelins as regulators of growth and function in endocrine tissues
89. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
90. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling
91. Novel 31-amino acid lenght endothelins cause constriction of vascular smooth muscle
92. 2+ channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs
93. Protein-protein interactions controlling nitric oxide synthases
94. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
95. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
96. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
97. Nitric oxide in the pathogenesis of vascular disease
98. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension
99. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells
100. Superoxide regulation of endothelinconverting enzyme
101. Biology of the endothelium
102. Endothelial function as an end-point in interventional trials: Concepts, methods and current data
103. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure
104. Catalysis by nitric oxide synthase
105. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene
106. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension
107. Role of endothelins in regulation of vascular tone in the in situ perfused rat adrenals
108. Endothelin-1[1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells
109. Endothelin-1 stimulates deoxyribonucleic acid synthesis and cell proliferation in rat adrenal zona glomerulosa, acting through an endothelin A receptor coupled with protein kinase C- and tyrosine kinase-dependent signaling pathways
110. Endothelial function in hypertension: The role of superoxide anion
111. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-depleted men
112. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension
113. Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: Role of hypoxia responsive element
114. Endothelin-dependent tone limits acetylcholine-induced dilation of resistance coronary vessels after blockade of NO formation in conscious dogs
115. Pathophysiology of endothelin in the cardiovascular system
116. Endothelial dysfunction: From physiology to therapy
117. Regulation of the endothelin system by shear stress in human endothelial cells
118. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition
119. Pranidipine, a new 1, 4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta
120. New insights into the regulation of inducible nitric oxide synthesis
121. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats
122. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mastcells
123. -786 → C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm
124. Endothelin-1- and endothelin-3-induced vasorelaxation via common generation of endothelium-derived nitric oxide
125. 2+ mobilization to mechanical stretch in endothelial cells
126. CsA and FK506 up-regulate eNOS expression: Role of reactive oxygen species and AP-1
127. The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex
128. Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues
129. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis
130. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line
131. B receptors by producing nitric oxide in isolated rat glomerulus, and in cultured rat mesangial cells
132. Nitric oxide synthase induction by ouabain in vascular smooth muscle cells from normotensive and hypertensive rats
133. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
134. Molecular control of nitric oxide synthases in the cardiovascular system
135. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis
136. Induction and stabilization of I-κB α by nitric oxide mediates inhibition of NF-κB
137. Endothelin-1 transcription is controlled by nuclear factor-κB in AGE-stimulated cultured endothelial cells
138. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P
139. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels
140. Peroxisome proliferator-activated receptors in tumorigenesis: Target of tumor promotion and treatment
141. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS III) gene
142. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
143. 2+ in human adrenocortical carcinoma
144. B receptor subtypes
145. Endothelin-1 and the adrenal gland
146. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo
147. Measurement of endothelin: Clinical and research use
148. Endothelins
149. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
150. Nitric oxide and endothelin-1 in coronary and pulmonary circulation
151. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
152. Secretory pathways in endothelin synthesis
153. The human heart endothelin system: ET-1 synthesis, storage, release and effect
154. Endothelin-1 is expressed and released by a human endothelial hybrid cell line (EA.hy-926)
155. Effects of nitrendipine, dotarizine and diltiazem on intracellular calcium in cultured bovine aortic endothelial cells
156. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells
157. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function
158. Adrenomedullin and the control of fluid and electrolyte homeostasis
159. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation
160. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis
161. Normalization of blood and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide
162. Intracoronary tetrahydrobiopterin improves endothelial dysfunction in patients with coronary risk factors
163. Elevated blood pressures in mice lacking endothelial nitric oxide synthase
164. Endothelin-1 inhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serum deprivation via MAP kinase pathway
165. Endothelin and endothelin receptor antagonism in heart failure
166. Forearm vasodilation in response to acetylcholine is increased by potassium in essential hypertensive patients
167. Endothelial dysfunction in hypertension
168. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension
169. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
170. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
171. Endothelin-1 secretion from cultured vascular endothelial cells of DOCA-salt hypertensive rats
172. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril
173. Characterization of the murine endothelial nitric oxide synthase promoter
174. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats
175. Antioxidants and the bioactivity of endothelium-derived nitric oxide
176. B receptor in endothelial cells. Receptor coupling to nitric oxide synthase
177. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
178. Endothelial dysfunction in hypertension
179. Organization of the bovine gene encoding the endothelial nitric oxide synthase
180. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
181. Polar secretion of endothelin-1 by cultured endothelial cells
182. Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells
183. Relationships between the endothelin and nitric oxide pathways
184. Remodeling and reparation of the cardiovascular system
185. Atherosclerosis and the two faces of endothelial nitric oxide synthase
186. Activated nuclear factor-κB is present in the coronary vasculature in experimental hypercholes-terolemia
187. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries
188. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
189. 2+]i in human coronary artery smooth muscle cells
190. Effect of endothelin-1(1-31) on extracellular signal-regulated kinases and proliferation of human coronary artery smooth muscle cells
191. Aldosterone and the heart
192. BQ-123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells
193. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension
194. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis
195. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent